Showing results (371-380 of 414) with videos related to
Sort By:
Pageof 42
Pain|October 17, 2007
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with painDennis C Turk, Robert H Dworkin, Dennis Revicki, et al.Urologic Oncology|April 6, 2013
High-resolution transrectal ultrasound: pilot study of a novel technique for imaging clinically localized prostate cancerChristian P Pavlovich, Toby C Cornish, Jeffrey K Mullins, et al.Pain|October 20, 2009
Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendationsRobert H Dworkin, Dennis C Turk, Michael P McDermott, et al.Gynecologic Oncology|October 24, 2007
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public WorkshopRobert C Bast, J Tate Thigpen, Susan G Arbuck, et al.International Journal of Medical Informatics|July 21, 2016
Electronic physiologic and subjective data acquisition in home-dwelling heart failure patients: An assessment of patient use and perception of usabilityCubby L Gardner, Michael C Flanagan, Cathy Franklin, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 30, 2018
Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease BurdenLuis F de Castro, Andrea B Burke, Howard D Wang, et al.Journal of the American Society of Nephrology : JASN|December 24, 1997
Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlationR B Colvin, A H Cohen, C Saiontz, et al.Msphere|July 6, 2026
Enteric populations of Escherichia coli are likely to be resistant to phages due to O antigen expressionBrandon A Berryhill, Teresa Gil-Gil, Kylie B Burke, et al.The Journal of Pain|February 1, 2015
Quality of pain intensity assessment reporting: ACTTION systematic review and recommendationsShannon M Smith, Matthew Hunsinger, Andrew McKeown, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2012
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosisAlbert Deisseroth, Edvardas Kaminskas, Joseph Grillo, et al.Pageof 42